ArticleFrontiers in cell and developmental biology2026
THAP7-AS1 sponges miR-4286 to upregulate PFKFB2, accelerating aerobic glycolysis and aggravating liver cancer progression.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver cancer ranks among the most prevalent and deadliest malignancies worldwide. As one of the largest metabolic organs, the liver undergoes profound metabolic reprogramming, encompassing oxidative phosphorylation and aerobic glycolysis (the Warburg effect)-a hallmark of liver cancer progression that drives tumor growth, metastasis, and chemoresistance. Accumulating evidence indicates that long non-coding RNAs (lncRNAs) play critical roles in cancer biology. In this study, we identify THAP7-AS1 as an oncogenic lncRNA that regulates aerobic glycolysis and promotes liver cancer tumorigenesis. Methods: RNA sequencing was employed to screen for differentially expressed genes in the serum of liver cancer patients versus healthy controls. The functional roles of THAP7-AS1 in aerobic glycolysis and liver cancer progression were investigated using CCK-8, colony formation, EDU incorporation, flow cytometry, and xenograft tumor assays. The underlying molecular mechanisms were explored via fluorescence Results: High THAP7-AS1 expression was significantly correlated with poor prognosis in liver cancer patients. Functionally, both Conclusion: THAP7-AS1 modulates aerobic glycolysis in liver cancer cells through the miR-4286/PFKFB2 axis. Collectively, our findings suggest that THAP7-AS1 holds promise as a serum diagnostic biomarker and a potential therapeutic target for overcoming liver cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.